Abstract. Despite considerable advances in understanding hepatocellular carcinoma, it is one of the common and deadliest cancers worldwide. Hence, increasing efforts are needed for early diagnosis and effective treatments. Saffron has been recently found to inhibit growth of liver cancer in rats. The aim of this study was to develop an effective method for treatment of liver cancer using magnetite nanoparticles (MNPs) coated with crocin, the main active component of saffron. MNPs were prepared and initially coated with dextran and a cross-linker to enhance conjugation of crocin using a modified coprecipitation method. Cultured HepG2 cells and diethylnitrosamine-injected mice were treated with crocin-coated MNPs and analyzed using cell proliferation assay and immunohistochemical analysis, respectively. Treatment of HepG2 cells with crocin-coated MNPs led to a significant inhibition of their growth as compared to control or those treated with free crocin or uncoated MNPs. Histological examinations of the livers of diethylnitrosamine-injected mice revealed several precancerous changes: multiple proliferative hepatic foci, hyper- or dysplastic transformations of bile ducts/ductules, and nuclear atypia associated with polyploidy, karyomegaly, and vacuolation. Immunohistochemistry using antibodies specific for cell proliferation (Ki-67) and apoptosis (M30-CytoDEATH and Bcl-2) revealed their upregulation during development of precancerous lesions. Using antibodies specific for inflammation (cyclooxygenase-2), oxidative stress (glutathione) and angiogenesis (vascular endothelial growth factor) indicated the involvement of multiple signaling pathways in the development of precancerous lesions. Treatment with crocin-coated MNPs was associated with regression of precancerous lesions, significant upregulation of apoptotic cells and downregulation of Bcl-2 labeling and markers of cell proliferation, inflammation, oxidative stress and angiogenesis. In conclusion, crocin-coated MNPs are more effective than free crocin for treatment of liver precancerous lesions in mice. These findings will help to develop new modalities for early detection and treatment of liver precancerous lesions.

Introduction

According to recent global statistics, liver cancer is the fifth most common cancer in men and the ninth in women. However, it is the second leading cause of cancer deaths in men and the sixth in women (1). More than 70% of the cases of primary liver cancer are hepatocellular carcinoma (2). It has approximately 8-month median survival without treatment which can be improved only by 3 months with the available chemotherapy (3). The primary side effects of most chemotherapeutic agents are their non-specificity and consequently cytotoxicity. Thus, the identification of new anticancer agents and use of enhanced drug delivery systems would increase specificity to cancer cells and reduce side effects of chemotherapy (4).

Natural products are commonly used for different purposes. Saffron, has been used in the treatment of some digestive and neoplastic disorders (5,6). Recent immunohistochemical and biochemical studies have demonstrated that saffron has significant therapeutic effects in a rat model of liver cancer through induction of apoptosis and downregulation of molecules involved in cellular proliferation, inflammation, and oxidative stress (7). Crocin is the main active component of saffron. It is a water-soluble carotenoid with antioxidant and anti-inflammatory properties (8). In addition, some studies have shown that crocin inhibits growth of different types of cancer cells derived from uterine cervix and mammary glands (9,10).

To enhance cancer therapy, the design of nanomaterials with specific functional properties that allow carrying therapeutic agents has become a promising approach (4). Magnetite nanoparticles (MNPs) are particularly useful drug carriers due...
to their biocompatibility, biodegradability and superparamagnetic properties. Because of their large surface area-to-volume ratio, high quantity of anticancer agents can be loaded onto the surfaces of MNPs. When administered into patients, these therapeutic agents are released from MNPs at the cancer site by passive or active targeting, thereby offering the possibility of minimizing the side effects (11).

To improve their efficacy as drug carriers, MNPs can be initially coated with a natural polymer. Recently, monolithic and monodisperse MNPs have been produced using a modified coprecipitation method at low temperature (12). These MNPs can be subjected to surface functionalization using organic coatings, such as sodium dodecyl sulfate (13). In this study, the aims were first to prepare and characterize MNPs coated with coatings, such as sodium dodecyl sulfate (13). In this study, the aims were first to prepare and characterize MNPs coated with dextran and crocin and then to test their effects on human hepatocellular carcinoma liver cancer cells in vitro and on a mouse model of liver carcinogenesis using diethyl nitrosamine (DEN).

Materials and methods

Preparation of dextran-coated MNPs. Solutions containing 0.3 M of FeCl₂·4H₂O and 0.6 M of FeCl₃ were prepared and injected into NaOH solutions containing 0.2, 0.5, 1.0 and 2.0% dextran with a feeding rate of 40 ml/h at 60°C. When a brownish precipitate was formed, the solution was vigorously stirred for 1 h. Suspensions of dextran-coated MNPs were decanted and centrifuged at 3,000 rpm for 15 min followed by a successive decantation/washing with 25% ammonia solution. Dextran-coated MNPs were dried at 60°C, finely ground, and characterized for their composition, morphology, thermal, and magnetic properties.

Benedict’s test. To detect the unattached dextran in the coated MNPs solutions, Benedict reagent containing 0.8 M sodium citrate, 0.9 M sodium carbonate and 0.1 M copper sulfate were prepared in deionized water. Few drops of the mixed test solution were added to 2 ml of Benedict reagent and boiled for 5 min in a water bath. Formation of colored precipitate qualitatively indicated the presence of dextran in the solution.

Coating of MNPs with crocin. The concentration of 1% dextran coating for MNPs was chosen for further coating. To enhance crocin coating, a cross-linker molecule between dextran and crocin was added. Pre-calculated amounts of dextran-coated MNPs were suspended in autoclaved deionized water and completely dried. Succinic anhydride was added to dextran-MNPs in a ratio of 20:1 followed by N,N-dimethylacetamide (DMAc) as a solvent. The mixture was then stirred for 8 h at 90°C in an oil bath. The remaining portion of MNPs coated with dextran and linker was washed three times with DMAc to remove unbound succinic anhydride. Each wash was followed by a centrifugation at 3,000 rpm for 15 min at room temperature and decantation. Freshly prepared 2 mmol 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in DMAc was added to MNPs coated with dextran and cross-linker and stirred at room temperature for 12 h under moisture-free conditions. Then, crocin at 50 or 100 mg/ml was added and stirred for 24 h at room temperature. Coated MNPs were centrifuged and washed with sterile deionized water 6 times at 4,000 rpm for 15 min. The resultant crocin-coated MNPs were precipitated and re-suspended in deionized water. UV-visible and Fourier transform infrared (FTIR) spectroscopic analyses were performed to confirm the presence of crocin on the surfaces of MNPs.

Characterization of crocin-coated MNPs. Crocin conjugation efficiency was determined by an indirect method involving detection of total free crocin concentration in the decanted solutions by measuring the absorbance at 440 nm (visible range) using a UV-visible spectrophotometer. The amounts of crocin coating on MNPs were calculated from the difference between the total amount of crocin initially used to coat MNPs and the amount of free crocin present in the decanted solutions (14).

The composition of MNPs was studied by FTIR spectroscopy using a Nicolet Nexus 470 infrared spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). The FTIR spectra of the samples were recorded in solid state by KBr pellet method in the 400-4,000 cm⁻¹ range. Thermogravimetric analysis was also carried out using a TGA-50 analyzer (Shimadzu, Kyoto, Japan), where the powder samples were heat to 600°C at a rate of 20°C/min using an aluminum pan. The percent weight loss was followed and correlated with the original composition of the MNPs. To visualize the crocin-coated MNPs, they were processed for imaging on carbon-coated copper grids by using Philips CM10 transmission electron microscopy (Eindhoven, The Netherlands).

Cell culture. HepG2 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in 75-cm² culture flasks using Dulbecco's modified Eagle’s medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin/streptomycin (Sigma-Aldrich). Cells were grown in 5% CO₂ at 37°C and 100% relative humidity. The culture medium was changed every 2 days and the cells were subcultured after 5-6 days using trypsin-EDTA (Sigma-Aldrich).

Methyl-thiazolyl-tetrazolium (MTT) assay. To determine the effective concentrations of crocin and MNPs, the MTT assay was used (15). Cells were seeded in 96-well plates at a density of 8,000 cells/well. After 24-h incubation, the culture medium was replaced with fresh medium containing free crocin (0.025, 0.05, 0.5, 3, 5, 8, 10, 15 or 20 mg/ml) or MNPs (0.05, 0.07, 0.09 or 0.1 mg Fe/ml). Then, the effects of 3 mg/ml crocin alone, 0.09 mg/ml total iron in MNPs alone, and 3 mg/ml crocin-coated MNPs on the cells were tested. After 72-h incubation, cells were washed with phosphate-buffered saline (PBS) and then 100 µl of fresh medium containing the tetrazolium dye, 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide at a final concentration of 5 mg/ml was added. Cells were then incubated at 37°C for 1 h and the developed formazan product was solubilized by adding 100 µl of isopropanol for 30 min. The absorbance was measured at 560 nm using Perkin-Elmer spectrophotometer (Waltham, MA, USA). The percent viability of the treated cells was determined in relation to control cells cultured without any treatment.

Animals. Balb/c mice were obtained from the animal facility of the College of Medicine and Health Sciences, UAE University. Animals were housed under a 12-h light/dark cycle.
Immunohistochemical studies. Liver tissue sections were incubated with biotinylated anti-rabbit antibodies (Jackson Immunoresearch, West Grove, PA, USA) for 2 h. Extravidin peroxidase conjugate (Sigma-Aldrich) was added for 1 h. The antigen-antibody binding sites were revealed by using 3,3'-diaminobenzidine (Sigma-Aldrich). Some of the tissues were counterstained with hematoxylin.

Experimental design. To induce carcinogenesis, 3-week-old male Balb/c mice (n=12) were injected intraperitoneally with 50 mg/kg body weight of DEN twice a week for 8 weeks. Mice were randomly divided into three groups and injected through the tail vein twice a week for two weeks either by 100 µl of saline, or 11 mg/kg body weight crocin alone, or 11 mg/kg crocin-coated MNPs. The concentration of iron in the injected MNPs was 17 mg/kg body weight (0.3 mg Fe/100 µl). This dose was previously reported to be non-toxic (16). For control, untreated weight- and sex-matched normal littermate mice were used. Similar experimental groups of mice (n=12) were treated with double the dose of free crocin (22 mg/kg) or crocin-coated MNPs (22 mg/kg). In these mice, the concentration of iron in the injected MNPs was also 17 mg/kg body weight.

One day after the last injection, mice were weighed, anesthetized, and dissected. The livers were immediately removed, weighed, and examined for the presence of any visible lesions. The right lobes were fixed in 10% buffered formalin and then examined using Olympus BX41 microscope (Olympus, Tokyo, Japan). Images were taken using DP70 digital camera. Adjacent sections were processed for Prussian blue staining and immunohistochemical analysis.

Prussian blue staining. To detect the presence of iron of the MNPs in liver tissues, tissue sections were deparaffinized, rehydrated and incubated for 35 min in an aqueous solution containing equal amounts of 20% hydrochloric acid and 10% potassium ferrocyanide mixed immediately before use. The concentration of iron in the injected MNPs was 17 mg/kg body weight (0.3 mg Fe/100 µl). This dose was previously reported to be non-toxic (16). For control, untreated weight- and sex-matched normal littermate mice were used. Similar experimental groups of mice (n=12) were treated with double the dose of free crocin (22 mg/kg) or crocin-coated MNPs (22 mg/kg). In these mice, the concentration of iron in the injected MNPs was also 17 mg/kg body weight.

One day after the last injection, mice were weighed, anesthetized, and dissected. The livers were immediately removed, weighed, and examined for the presence of any visible lesions. The right lobes were fixed in 10% buffered formalin and then examined using Olympus BX41 microscope (Olympus, Tokyo, Japan). Images were taken using DP70 digital camera. Adjacent sections were processed for Prussian blue staining and immunohistochemical analysis.

Properties of MNPs. MNPs prepared by using a modified coprecipitation method at low temperature were coated in situ with dextran and crocin as summarized in Fig. 1A. These MNPs possessed a good dispersibility and stability in water and spherical shape with uniform size of 16 nm average diameter (Fig. 1B). Thermogravimetric analysis confirmed the presence of dextran on MNPs and helped to determine its optimal concentration. Pure MNPs showed a average weight loss of 14% due to removal of water that was physically adsorbed onto their surfaces (Fig. 2A). Pure dextran showed an initial weight loss of 10% at 100-150°C due to water removal followed by a major weight loss of 92% at 300°C due to combustion of dextran and degradation of polysaccharide chains. Increasing concentrations of dextran on MNPs showed a similar pattern as pure dextran confirming the presence of dextran on their surfaces. Dextran concentration of 1% was optimal to use because higher concentration was not associated with any significant increase in weight loss (Fig. 2B).

FTIR spectra of pure crocin showed bands at 1,515 and 1,697 cm\(^{-1}\) (due to C=O bond), 1,515 cm\(^{-1}\) (C-H bond). The broad stretch between 3,262 and 3,441 cm\(^{-1}\) corresponded to the presence of OH group (Fig. 2C). This pattern was in line with previously described FTIR analysis (17). FTIR spectrum of crocin-coated MNPs showed the unique bands of C=O at 1,534 and 1,637 cm\(^{-1}\) which was only present in crocin, confirming the successful coating of MNPs with crocin (Fig. 2C).

Effects of crocin treatments on the viability of HepG2 cells. Treatments of HepG2 cells with increasing concentrations of crocin (from 0.025 to 20 mg/ml) revealed a reduction in cellular
Incubation of HepG2 cells with crocin revealed a gradual reduction in cellular viability starting from the concentration of 3 mg/ml concentration. These changes were confirmed by MTT assay (Fig. 3A).
Figure 3. MTT assay using HepG2 cells treated for 72 h with: (A) different concentrations of free crocin (0.025-20 mg/ml) and (B) free crocin, MNPs coated with dextran, and MNPs coated with dextran and crocin. Values are expressed as mean ± SEM. *P≤0.05, **P≤0.01, ***P≤0.001.

Figure 4. Microscopic analysis of liver tissue sections obtained from normal mice (A-C) and mice injected with DEN (D-I), DEN and free crocin (J) and DEN and crocin-coated D-MNPs (K and L). Tissues were stained with H&E (A-K) and Prussian blue (L). Normal liver tissues demonstrate: (A) portal area with a branch of the pv, a bile duct (arrow), and radiating numerous plates of acidophilic hepatocytes, (B) central vein (cv) surrounded by numerous plates of hepatocytes, (C) hepatocytes which appear polyhedral, mono- and bi-nucleated (n), and separated by interconnected sinuous (s). DEN-injected liver tissues demonstrate different signs of precancerous changes: (D) pale hepatocellular foci (dashed circle) made of lightly stained hepatocytes, (E) dark hepatocellular foci (dashed circle) of small hepatocytes, aggregations of small lymphoid cells (ly), multiple profiles of bile ducts (arrows), and scattered mitotic (m) and apoptotic cells (ap), (F) hyperplastic bile ducts which may acquire dilated lumen (arrows) with apoptotic dark cells (ap), (G) numerous dysplastic bile ducts (arrows) with disrupted architecture, (H) nuclear atypia and some nuclei appear huge with vacuolar spaces (n), and (I) nuclear po with m and ap cells. Liver tissues of mice injected with DEN and then treated with 11 mg/kg crocin: (J) free crocin induces an improvement in the overall architecture of the liver tissue and the portal area appears in the lower left side, (K) crocin-coated D-MNPs also induces an improvement in the liver tissue with a normal portal area seen at the top. The brownish structures indicate the NPs. (L) Prussian blue staining to demonstrate the accumulation of MNPs in the hepatocytes (red arrows) and Kupffer cells (black arrows) of liver tissue of a mouse treated with crocin-coated D-MNPs. Scale bar, 100 (A, B, E-G, J and K) and 50 µm (C, D, H, I and L).
of 3 mg/ml in a dose-dependent manner. It reached ~70% at a dose of 3 mg/ml when compared with control and became 55% at a dose of 5 mg/ml (Fig. 3A). The effect of MNPs on the viability of HepG2 cells was also tested. Increasing concentrations of iron in the media for 72 h showed a decrease in cell viability starting from 0.07 mg/ml. There was no significant effect at 0.05 mg/ml compared to the control (data not shown). Based on these data and published information on the dose of MNPs (18), it was decided to use crocin-coated MNPs containing 3 mg crocin and 0.09 mg iron per ml. The effects of such amounts of crocin and iron either alone or conjugated were tested on HepG2 cells. The data revealed that crocin alone reduced the percentage of viable cells as compared to control. This reduction was significantly (P<0.01) enhanced when crocin-coated MNPs were used (Fig. 3B).

**Effects of crocin treatments on the histological features of the livers.** Tissue sections of normal control liver showed the usual pattern of lobules with peripheral portal areas including small bile ducts/ductules (Fig. 4A-C). The administration of DEN into mice caused several histopathological signs: i) multiple pale or basophilic hepatocellular foci (Fig. 4D and E), ii) lymphocytic infiltrations and hyperplastic or dysplastic changes (Fig. 4E-G), iii) hepatocytes with nuclear atypia or pleomorphism, karyomegaly, polyploidy, and vacuolation (Fig. 4D, H and I), iv) prominent apoptotic cells (Fig. 4E and F), and v) increased mitotic figures in portal areas and hepatocytes (Fig. 4E and I).

Treatment of DEN-injected mice with free crocin or crocin-coated D-MNPs induced apparent recovery of liver histology (Fig. 4F). This effect was more apparent in mice treated with crocin-coated D-MNPs (Fig. 4K). The presence of crocin-coated D-MNPs in the liver tissues was demonstrated by Prussian blue staining (Fig. 4L). Variable accumulations of blue-stained MNPs were observed in the cytoplasm of hepatocytes and some scattered interstitial cells, probably phagocytic Kupffer cells (Fig. 4L).

**Effects of crocin treatments on cell proliferation.** To investigate cell division in the livers of control and treated mice, immunohistochemistry using anti-Ki-67 antibodies was applied. Immunolabeled cells were very few in the livers of normal mice (Fig. 5A), but were apparent and numerous after DEN injection (Fig. 5B). While these dividing cells were mainly found in the walls of amplifying bile ducts/ductules in the portal areas, some were hepatocytes and interstitial/lymphoid cells. Cell proliferation was also apparent in hepatocellular foci, made of numerous small compact hepatocytes. Quantifications revealed >6-fold increase in the areas of Ki-67 immunoreactivity in DEN-injected mice (Table I). This significant hyperproliferation was slightly reduced in mice treated with 11 and 22 mg/kg free crocin (Fig. 5C, E and F). The percent decrease was estimated at 20 and 27, respectively. This reduction was significantly enhanced when mice were treated with similar doses of crocin but conjugated to MNPs (Fig. 5D-F). So, the percent decrease of cell proliferation reached 31 and 62, respectively (Table I).

**Effects of crocin treatments on apoptosis.** Immunolocalizations of M30 epitope of the cleaved cytokeratin 18 in normal livers showed no or an occasional positively labeled cell (Fig. 6A). In DEN-injected mice, there was a consistent cytoplasmic labeling, but only in a few scattered cells (Fig. 6B). These M30-positive cells became even more apparent in mice treated with crocin (Fig. 6C) and crocin-coated D-MNPs (Fig. 6D). Quantifications revealed that the percent increase in cell death with crocin-coated D-MNPs was highly significant (P<0.001) when compared with the values of DEN-injected mice (Fig. 6E and F and Table I).

When the anti-apoptotic Bcl-2 protein was investigated, no immunolabeling was detected in normal liver cells (Fig. 7A). However, the immunolocalization of Bcl-2 was apparent in

### Table I. The percentages of areas immunolabeled with antibodies specific for different biomarkers in the livers of normal mice and mice injected with DEN, DEN plus crocin, and DEN plus crocin-coated D-MNPs.

<table>
<thead>
<tr>
<th>Biomarkers</th>
<th>Conc.</th>
<th>Normal</th>
<th>DEN</th>
<th>DEN + Crocin</th>
<th>DEN + Crocin-D-MNPs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ki-67</td>
<td></td>
<td>0.19±0.03</td>
<td>1.20±0.13</td>
<td>0.97±0.10</td>
<td>0.83±0.09</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.10±0.01</td>
<td>1.16±0.08</td>
<td>0.85±0.08</td>
<td>0.43±0.03</td>
</tr>
<tr>
<td>M30</td>
<td></td>
<td>0.06±0.01</td>
<td>0.48±0.05</td>
<td>0.79±0.09</td>
<td>0.87±0.08</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.21±0.03</td>
<td>0.88±0.10</td>
<td>1.24±0.15</td>
<td>1.56±0.12</td>
</tr>
<tr>
<td>Bcl-2</td>
<td></td>
<td>3.38±0.49</td>
<td>22.23±1.53</td>
<td>17.96±2.92</td>
<td>13.80±2.45</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.98±1.39</td>
<td>33.53±3.0</td>
<td>20.54±2.29</td>
<td>17.02±1.85</td>
</tr>
<tr>
<td>GST</td>
<td></td>
<td>0.44±0.08</td>
<td>6.63±1.56</td>
<td>2.52±0.48</td>
<td>2.54±0.27</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.83±0.20</td>
<td>14.29±1.91</td>
<td>9.46±1.01</td>
<td>7.24±0.78</td>
</tr>
<tr>
<td>COX-2</td>
<td></td>
<td>9.21±0.56</td>
<td>39.70±2.28</td>
<td>32.26±1.78</td>
<td>21.13±2.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7.74±0.61</td>
<td>46.37±1.80</td>
<td>30.40±2.12</td>
<td>18.18±1.52</td>
</tr>
<tr>
<td>VEGF</td>
<td></td>
<td>5.59±0.61</td>
<td>48.21±4.27</td>
<td>43.70±4.24</td>
<td>39.04±3.98</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6.51±1.12</td>
<td>52.45±2.47</td>
<td>39.85±3.00</td>
<td>29.53±2.72</td>
</tr>
</tbody>
</table>

*Data are presented for low (L) and high (H) concentrations (11 and 22 mg/kg body weight, respectively) of crocin (free or conjugated to D-MNPs).
DEN-injected mice as compared to any of the other groups of mice (Fig. 7B-D). The immunostaining was specifically cytoplasmic. The expression of Bcl-2 in liver tissues of mice treated with crocin-coated D-MNPs was reduced as compared to DEN-injected or free crocin-treated mice. Quantifications confirmed the microscopic observations and showed significant differences between the levels of Bcl-2 expression in normal mice very low, but highly increased in DEN injected mice. Treatments with crocin (free or conjugated to D-MNPs) reduced the expression area of Bcl-2 and is highly significant when the high dose of crocin-coated D-MNPs was used. Values are expressed as mean ± SEM; *P≤0.05, **P≤0.01, ***P≤0.001.

**Effects of crocin treatments on GST immunolabeling.** Microscopic examination of normal liver tissues probed with anti-GST antibodies revealed no or occasional cells expressing GST (Fig. 8A). However, many hepatocytes were positively stained for GST in DEN-induced mice (Fig. 8B). The staining was homogeneously cytoplasmic with some variations in the intensity and distribution. Abnormal hepatocytes with large vacuolated nuclei were more intensely stained than other surrounding cells with normal morphology. In these altered cells, the nuclei were also labeled with anti-GST antibody (Fig. 8B). In DEN-injected mice treated with 11 mg/kg of crocin, there was a decrease in the staining for GST (Fig. 8C). This reduction in GST immunolabeling was more apparent in mice treated with crocin-coated D-MNPs. Quantifications revealed an increase by ≥16-fold in the percent areas of GST immunolabeling in DEN-induced mice as compared to normal mice (Fig. 8E and Table I). Quantifications showed significant differences between the levels of GST expression in mice treated with 11 and 22 mg/kg of crocin-coated D-MNPs as compared to those of DEN-injected mice (Fig. 8E and F and Table I).

**Effects of crocin treatments on COX-2 immunolabeling.** In normal mice, COX-2 immunoreactivity was weak in normal liver tissues (Fig. 9A). In DEN-injected mice, there was a massive increase in COX-2 expression (Fig. 9B). This reduction in COX-2 labeling was more apparent in mice treated with crocin-coated D-MNPs. Quantifications showed significant differences between the levels of COX-2 expression in mice treated with 11 and 22 mg/kg of crocin-coated D-MNPs as compared to those of DEN-injected mice (Fig. 9E and F and Table I).
apparent COX-2 immunolabeling (Fig. 9B). COX-2 expression was localized in the cytoplasm of hepatocytes around both the central vein and portal areas. Quantification revealed that COX-2 expression was significantly increased by >4-fold in DEN-injected mice compared to normal mice (Fig. 9E and F). However, COX-2 was significantly reduced (P<0.001) in the liver tissues treated with 11 or 22 mg/kg crocin-coated D-MNPs compared with DEN-injected or free crocin-treated mice (Fig. 9C-F).

**Effects of crocin treatments on VEGF immunolabeling.** VEGF immunoreactivity was very weak in normal mice, but a strong cytoplasmic expression was found in DEN-injected mice (Fig. 10A and B). Moreover, VEGF expression was inhibited after the treatment with free crocin or with crocin-coated D-MNPs (Fig. 10C and D). Measurements of the areas stained for VEGF showed that their significant (P<0.001) increase in DEN-injected mice was ≥8-fold (Fig. 10E and F). Whereas the inhibition of VEGF immunostaining was not significant when a low dose of free or conjugated crocin was used. It became significant only when the crocin dose was doubled (Fig. 10E and F and Table I).

**Discussion**

Drug delivery via MNPs utilizes their multifunctional properties and the distinctive characteristics of cancer tissue, such as leaky vasculature (19). In this study, MNPs were prepared using a modified coprecipitation method. To reduce their aggregation, they were first coated with dextran, a natural polysaccharide polymer known for its biocompatibility (20). The overall size of MNPs must be sufficiently small to evade rapid filtration by the spleen but large enough to avoid renal clearance. MNPs >100 nm are sequestered by phagocytosis, while particles smaller than 10 nm are rapidly removed through renal clearance (11). So, the 16-nm size of crocin-coated D-MNPs produced in this study are suitable for drug delivery.
Crocin is a water-soluble carotenoid with significant anti-cancer effects (21,22). In this study, MTT assay showed that crocin also inhibits growth of HepG2 cells in a dose-dependent manner. Several mechanisms were proposed for the action of crocin involving effects on cell proliferation and apoptosis (21,22). However, crocin was found to have no toxic effects on normal cells such as human skin fibroblasts (22).

HepG2 cells incubated with different iron concentrations in dextran-conjugated MNPs showed good biocompatibility due to their dextran coating. The slight decrease in cell viability might be because some MNPs lost their dextran coating, consequently exposing iron to the cells. Similarly, it was demonstrated that iron used at 0.01-0.1 mg/ml was safe for growth of MCF-7 cells (18). Accordingly, in this study, the biocompatible dextran-conjugated MNPs containing 0.09 mg/ml iron were coated with crocin for in vitro and in vivo studies. When HepG2 cells were incubated with crocin and dextran-coated MNPs containing 3 mg/ml crocin and 0.09 mg/ml Fe, there was a reduction in cell count due to the release and interaction of crocin with the cells. The effect of crocin-coated MNPs was more pronounced than that of free crocin possibly due to: i) gradual release of crocin leading to prolonged time of interaction, and ii) enhanced delivery of crocin-coated D-MNPs to the cells by different mechanisms such as adsorption and endocytosis (23).

The carcinogenic effect of DEN could be due to different mechanisms: i) alkylating DNA structures leading to the formation of mutagenic DNA adducts, ii) generating ROS that damages DNA, protein, and lipid molecules, iii) inducing mutations in H-ras proto-oncogene leading to unlimited cell division, iv) inducing overexpression of the Bcl-2 gene, and v) stimulating the proliferation of hepatic oval cells and bile duct cells leading to hyperplasia and the formation of microscopic precancerous lesions (24,25).

Multiple injections of DEN were found to induce preneoplastic changes in young mice probably in two stages: initially by enhancing apoptosis and then, DNA synthesis is stimulated and ultimately precancerous lesions are formed. This model also mimics the human conditions in which cycles of degeneration

Figure 9. Immunohistochemical analysis of Cox-2 labeling in liver tissues of normal (A), DEN-injected (B), free crocin-treated (C), and crocin-coated D-MNP-treated (D) mice. In these representative mouse tissue sections, the dose of free and conjugated crocin was similar, 11 mg/kg body weight. (A) In normal mouse tissue, there are very few or no Cox-2-labeled cells. (B) In DEN-injected tissue, there are numerous Cox-2-labeled cells (arrows). (C) In free crocin-treated tissue, the Cox-2-positive cells are reduced (arrows). (D) In tissue treated with crocin-coated D-MNPs, there are only a few or no Cox-2-labeled cells. Scale bar, 100 µm. The graphs demonstrate the quantifications of the percent of Cox-2-labeled areas in normal and DEN-injected mice as compared to mice treated with 11 (E) or 22 mg/kg (F) of free crocin or D-MNPs coated with crocin. Note that the level of Cox-2-labeling in normal mice is very low, but highly increased in DEN injected mice. Treatments with crocin (free or conjugated to D-MNPs) reduced the expression area of Cox-2 and is highly significant when the low or high doses of crocin-coated D-MNPs are used. Values are expressed as mean ± SEM; *P≤0.05, **P≤0.01, ***P≤0.001.

Figure 10. Immunohistochemical analysis of VEGF labeling in mouse liver tissues. (A) In normal tissue, there are no VEGF-labeled cells. (B) In DEN-injected tissue, there are numerous VEGF-labeled hepatocytes (arrows). (C) In free crocin-treated tissue, the VEGF-labelled cells are reduced (arrows) in number and intensity. (D) In liver tissue treated with crocin-coated D-MNPs, there are only a few VEGF-labeled cells. In (C) and (D), the dose of free and conjugated crocin was similar, 11 mg/kg body weight. Scale bar, 100 µm. The graphs demonstrate the percent of VEGF-labeled areas in normal and DEN-injected mice as compared to mice treated with 11 (E) or 22 mg/kg (F) of crocin (free or or conjugated to D-MNPs). Note that the difference between VEGF-labeling in normal and DEN-injected mice is highly significant. Treatment with crocin (free or conjugated to D-MNPs) reduced the expression area of VEGF and becomes significant when high doses of free or conjugated crocin are used. Values are expressed as mean ± SEM; *P≤0.01, **P≤0.001.
and regeneration might activate preneoplastic transformations. The younger the mice, the faster cancer will develop because of the high proliferation rates in young animals. Male mice were used in this study due to the stimulating effect of androgens and the inhibitory effect of estrogens on hepatocarcinogenesis (26).

Apoptosis is essential for tissue homeostasis and also plays a role in carcinogenesis (27). During apoptosis, the mitochondrial outer membrane becomes permeable and releases multiple proteins into the cytosol leading to activation of caspases and cleavage of different substrates including cytokeratin 18. In this study, M30 localization in DEN-injected mice showed an increased apoptotic cells which might have contributed to the increased cell proliferation to replace dead cells. Saffron treatment was found to increase the number of M30 positive cells in DEN-injected rats (7). This study demonstrates that the numbers of M30-positive apoptotic cells are increased in mice treated with crocin-coated D-MNPs compared to DEN-injected or free crocin-treated mice (fig. 6).

Bcl-2 is known to prolong cellular survival by blocking apoptosis induced by a wide variety of death signals (27). This study shows that Bcl-2 is highly expressed in DEN-injected mice. This is in line with previous studies on DEN-induced tumors in the mouse liver with upregulation of Bcl-2 (28). In this study, the inhibitory effect of crocin on Bcl-2 expression was significantly enhanced when it was conjugated with D-MNPs (Fig. 7).

Previous studies revealed that GST induction occurs in preneoplastic cell populations (29). In this study, the expression of GST protein was significantly upregulated in liver tissues of DEN-injected mice compared to normal mice. Treatment with crocin-coated D-MNPs was associated with decreased pre-cancerous lesions and a significant downregulation of GST expression. Therefore, GST appears to be a good marker to follow progression and regression of hepatic preneoplastic lesions.

COX-2 overexpression is associated with an increase in prostaglandin levels which affects many mechanisms involved in carcinogenesis, such as angiogenesis, inhibition of apoptosis, stimulation of cell growth and invasiveness of tumor cells (30,31). Therefore, COX-2 is an important molecular target for anticancer therapies. Its expression is undetectable in most normal tissues and is highly induced in the livers of DEN-injected rats (32). Similar results were reported in this study. Dietary feeding with crocin for 4 weeks was able to inhibit colonic adenocarcinomas in mice and decrease the mRNA expression of inflammation regulators such as COX-2 (33). Therefore, free crocin has a role in inhibiting COX-2 expression in animals with cancer, which explains the reduction in COX-2 expression in crocin-treated animals. Moreover, this effect was increased in 11 and 22 mg/kg crocin-coated D-MNPs-treated mice, indicating the role of D-MNPs in improving the anticancer activity of crocin.

VEGF plays critical roles in tumor angiogenesis, invasion and metastasis, and vascular permeability (34). The expression of VEGF induced by DEN injections was decreased with 11 and 22 mg/kg crocin that was attached to MNPs compared to free crocin treated group, indicating the enhancement of anticancer effect of crocin upon loading it on MNPs.

The use of MNPs as a carrier system for crocin delivery is very promising for cancer therapy due to several reasons. The nano-size of the magnetite particles is well tolerated by the organism. When injected into animals, they degrade with time into products that can be re-used by the body cells. They have high surface area to volume ratio that allows them to upload high amount of crocin onto their surfaces. MNPs are able to deliver crocin in the precancerous tissues by passive targeting due to enhanced permeability and retention effect. The stability of crocin is enhanced by its conjugation onto the surfaces of MNPs. While free crocin has low stability and its functionality is reduced by exposure to heat, oxygen, or light, MNPs preserve crocin in its intact active form (35). The concentrations of crocin and MNPs used in this study were non-toxic and the used crocin-coated MNPs were monodispersed and stable in several solutions including water, DMEM and saline.

In conclusion, this study demonstrates that MNPs enhance anticancer effects of crocin and improve its biological effects using in vitro (HepG2 cells) and in vivo (liver precancerous lesions) models. Immunohistochemical analysis demonstrated the involvement of different cellular pathways in the development of precancerous liver and demonstrated their possible use as prognostic recovery markers in mice treated with
free crocin or crocin-coated D-MNPs. Since the hepatocytes undergo a slow renewal process it is anticipated that there will be a complete but slow recovery of the liver tissue when the treatment is discontinued. A proposed mechanism for the effects of crocin-coated MNPs is depicted in Fig. 11. Crocin released from D-MNPs inhibits cell proliferation and stimulates caspase-mediated apoptosis. The anti-inflammatory and anti-angiogenesis effects of crocin are demonstrated by down-regulation of COX-2 and VEGF. Therefore, the functionalized D-MNPs are useful tools for delivery of crocin to enhance its anticancer effects. These results could help in designing new modalities for early detection and treatment of liver precancerous lesions to hopefully reduce the high incidence and mortality rate of hepatocellular carcinoma.

Acknowledgements

The authors are indebted to Mr. Saeed Tariq in the Electron Microscopy Unit, College of Medicine, UAEU and Mr. Bassam Al Hindawi in the Chemistry Department for their superb technical assistance. This study was supported by research funds from UAEU Research Sector and College of Graduate Studies of UAEU.

References